Pathstone Family Office’s Sarepta Therapeutics SRPT Stock Holding History

Pathstone Family Office’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$388K	Buy	+3,204	New	+$362K	﹤0.01%	1165
2021 Q1	–	Sell	-23	Closed	-$4K	–	1267
2020 Q4	$4K	Sell	23 -181	-89%	-$26.8K	﹤0.01%	985
2020 Q3	$29K	Buy	204 +149	+271%	+$22.6K	﹤0.01%	432
2020 Q2	$9K	Sell	55 -20	-27%	-$2.72K	﹤0.01%	535
2020 Q1	$7K	Buy	+75	New	+$8.57K	﹤0.01%	588
2019 Q4	–	Sell	-51	Closed	-$4K	–	602
2019 Q3	$4K	Buy	+51	New	+$6.02K	﹤0.01%	549
2019 Q2	–	Sell	-45	Closed	-$5K	–	871
2019 Q1	$5K	Hold	45	–	–	﹤0.01%	606
2018 Q4	$5K	Buy	+45	New	+$5.63K	﹤0.01%	383

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Pathstone Family Office's SRPT Position: Q3 2023 in Review

Pathstone Family Office opened a new position in Sarepta Therapeutics (SRPT) in Q3 2023: 3,204 shares worth $388K. The stake represents ﹤0.01% of the portfolio and ranks #1165 among its holdings. This is a return to the name: Pathstone Family Office previously reported a position in SRPT as recently as Q4 2020.

Pathstone Family Office first reported a position in SRPT in Q4 2018 and has held it in 8 quarters since. 394 funds tracked by Wall St. Rank hold SRPT as of Q3 2023.

Pathstone Family Office held 3,204 shares of Sarepta Therapeutics worth $388K as of Q3 2023.
Sarepta Therapeutics was a new Pathstone Family Office position in Q3 2023.
Sarepta Therapeutics made up ﹤0.01% of Pathstone Family Office's portfolio in Q3 2023, its #1165 holding.
Pathstone Family Office first reported a position in Sarepta Therapeutics in Q4 2018 and has held it in 8 quarters since.
394 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2023.

Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.